Related Experiment Video
Updated: Apr 24, 2026

Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
Navigating the Core Challenges of Atropine Therapy in Myopia: A Mechanistic and Clinical Analysis of Dose, Response,
Qinling Jiang1, Jing Yang1, Xingwei Cao1
1Ophthalmology Department, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China, scu.edu.cn.
Abstract:
Myopia has emerged as a major global public health concern. Atropine, recognized as one of the foremost interventions for myopia control, has been validated for its efficacy and safety through a multitude of clinical studies. This article examines the most recent advancements in understanding atropine's mechanisms of action, optimizing dosage, customizing treatment plans, and assessing its long-term effectiveness in managing myopia. While atropine has shown impressive clinical results, there are still significant knowledge gaps surrounding its mechanisms of action, the personalization of treatments, rebound effects following cessation, and ocular side effects. Future investigations should prioritize clarifying the mechanisms of atropine, developing pertinent biomarkers for guiding individualized therapies, and investigating integrated control strategies that combine atropine with other treatments to enhance long-lasting therapeutic benefits. As a crucial medication for the prevention and management of myopia, atropine holds significant promise for a holistic approach to myopia treatment, offering new insights and directions to tackle this public health challenge.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cholinergic Antagonists: Pharmacokinetics
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

